EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Low-Dose Rivaroxaban vs. Aspirin in Addition to Clopidogrel After Percutaneous Coronary Intervention in Coronary Atherosclerotic Heart Disease Patients with Gastrointestinal Disease

Yue Li, Tienan Zhou, Yan Liu, Junxian Qi, Lei Zhang, Ruoxi Gu, Dongyuan Sun, Xiaozeng Wang iD

Cardiovascular Drugs and Therapy · 2026-02 · 40 (1) · 201-211

DOI: 10.1007/s10557-025-07682-5 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 21.03.2025. Verfasst von Yue Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of No…. Hauptthemen laut MEDLINE: Rivaroxaban, Clopidogrel, Percutaneous Coronary Intervention, Aspirin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Liaoning Province, China National Key R&D Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Dual antiplatelet therapy (DAPT) is the cornerstone for patients with coronary atherosclerotic heart disease (CHD) undergoing percutaneous coronary intervention (PCI) while increasing the risk of bleeding, particularly when combined with gastrointestinal disease (GID). Rivaroxaban 10 mg once daily is widely used in Asia. This study compared the effects of low-dose rivaroxaban (10 mg daily) plus clopidogrel vs. DAPT in CHD patients with GID undergoing PCI.

Methods

In this prospective, single-center, randomized controlled trial, eligible CHD patients with GID undergoing PCI were randomized (1:1) to either the dual pathway inhibition (DPI) group (rivaroxaban 10 mg plus clopidogrel 75 mg daily) or the DAPT group (aspirin 100 mg plus clopidogrel 75 mg daily). The primary outcome was Bleeding Academic Research Consortium (BARC) type 2–5 bleeding. The secondary outcome was major adverse cardiovascular or cerebrovascular events (MACCE), which included cardiac death, nonfatal myocardial infarction, ischemia-driven target vessel revascularization, all-cause death, stent thrombosis, and stroke during the 6-month follow-up.

Results

A total of 1042 patients were enrolled and analyzed (DPI, 522; DAPT, 520). Low-dose rivaroxaban (10 mg daily) plus clopidogrel was non-inferior to DAPT in BARC type 2–5 bleeding [8 (1.5%) vs. 6 (1.2%), absolute risk difference 0.38%, 95% confidence interval (CI) (− 1.02–1.78), p < 0.0001 for non-inferiority]. Abdominal pain was significantly lower in the DPI group ( p = 0.009). Other abdominal discomforts, gastrointestinal bleeding, or MACCE were similar.

Conclusions

In CHD patients with GID undergoing PCI, low-dose rivaroxaban (10 mg daily) plus clopidogrel was non-inferior to DAPT.

Trial registration

Chinese Clinical Trial Registry ChiCTR2100044319. Registered on March 16, 2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanClopidogrelPercutaneous Coronary InterventionAspirinPlatelet Aggregation InhibitorsCoronary Artery DiseaseFactor Xa InhibitorsGastrointestinal DiseasesDual Anti-Platelet TherapyHumansMaleFemaleMiddle AgedAgedProspective StudiesTreatment OutcomeDrug Therapy, CombinationRisk FactorsTime FactorsHemorrhage

Stichwörter der Autor:innen

Coronary atherosclerotic heart diseaseGastrointestinal diseaseLow dosePercutaneous coronary interventionRivaroxaban

Substanzen

RivaroxabanClopidogrelAspirinPlatelet Aggregation InhibitorsFactor Xa Inhibitors

Autor:innen und Institutionen

  • National Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110016, China.
  • College of Life Science and Biopharmaceutical, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
  • National Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110016, China. wxiaozeng@1…

ORCID-Profile: Xiaozeng Wang

Förderung

  • Natural Science Foundation of Liaoning Province
  • China National Key R&D Project

Zitieren

APA

Li, Y., Zhou, T., Liu, Y., Qi, J., Zhang, L., Gu, R., Sun, D., & Wang, X. (2026). Low-Dose Rivaroxaban vs. Aspirin in Addition to Clopidogrel After Percutaneous Coronary Intervention in Coronary Atherosclerotic Heart Disease Patients with Gastrointestinal Disease. Cardiovascular Drugs and Therapy, 40(1), 201-211. https://doi.org/10.1007/s10557-025-07682-5

Vancouver

Li Y, Zhou T, Liu Y, Qi J, Zhang L, Gu R, et al. Low-Dose Rivaroxaban vs. Aspirin in Addition to Clopidogrel After Percutaneous Coronary Intervention in Coronary Atherosclerotic Heart Disease Patients with Gastrointestinal Disease. Cardiovascular Drugs and Therapy. 2026;40(1):201-211. doi:10.1007/s10557-025-07682-5

BibTeX
@article{Li2026,
  author = {Li, Yue and Zhou, Tienan and Liu, Yan and Qi, Junxian and Zhang, Lei and Gu, Ruoxi and Sun, Dongyuan and Wang, Xiaozeng},
  title = {Low-Dose Rivaroxaban vs. Aspirin in Addition to Clopidogrel After Percutaneous Coronary Intervention in Coronary Atherosclerotic Heart Disease Patients with Gastrointestinal Disease},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2026},
  volume = {40},
  number = {1},
  pages = {201--211},
  doi = {10.1007/s10557-025-07682-5}
}
Kostenlos starten →